Should Labcorp Stock Holders Look At Quest Diagnostics Instead?
Labcorp (LH) and Quest Diagnostics (DGX) both provide lab tests, but differ in additional services. Labcorp raised 2026 revenue guidance for its drug-development labs, while Quest increased its forecast due to testing volume growth. Both face Medicare fee cuts in 2027. Quest trades at lower trailing earnings multiple, grows faster, and has wider margins, but Labcorp is cheaper on sales and adjusted forecast earnings.
How this was made

The 30-second read
Why it matters
Both tickers are discussed through segment-specific guidance revisions, valuation multiples, and growth/margin comparisons, with Quest also disclosing unauthorized access to a test ordering system and compromised patient data.
Market read
Useful for positioning between LH and DGX based on which guidance drivers look more durable, but it is not a fresh disclosure beyond the already-reported October updates.
What to watch
Cybersecurity impact on Quest is mentioned but not quantified; traders may need to assess customer retention, regulatory exposure, and remediation costs beyond the article’s qualitative note.
Background
The article contrasts Labcorp’s and Quest Diagnostics’ October 2026 guidance updates, focusing on different business mixes and shared Medicare PAMA fee-cut risk.
Ticker impact
Labcorp raised 2026 outlook on Oct. 28, with Biopharma Laboratory Services revenue midpoint growth lifted to 7.9% and diagnostics up only 20 bps.
Likely mild upward bias as investors reprice the drug-development labs growth versus the smaller diagnostics revision.
The article provides specific, company-attributed guidance changes and segment mix details, but it is framed as a comparison rather than a fresh catalyst beyond the already-reported October updates.
Quest raised 2026 revenue growth expectations on Oct. 22 to 9.5% at the midpoint, citing testing volume up 14.5% with new Corewell Health and Fresenius relationships.
Likely upward bias as the market favors the higher-growth, margin-accretive consumer health trajectory despite the PAMA fee cut risk.
The piece includes concrete guidance and volume drivers plus a disclosed cybersecurity incident, but it does not provide a new post-October development that would force an immediate repricing today.
Market effects
Reinforces the lab-services sector’s key debate: growth mix (drug-development labs and consumer health) versus Medicare PAMA fee pressure starting 2027.
Primarily US-listed healthcare services sentiment, with read-through to managed care and hospital testing demand expectations.
Limited, as the drivers cited are US Medicare reimbursement and US partner-driven testing volumes.
Counterpoint
The comparison may overemphasize segment growth while underweighting the 2027 Medicare lab-fee hit and potential reimbursement uncertainty that could compress both companies’ margins.
Key entities
- companyLabcorp
Raised 2026 outlook on Oct. 28, with Biopharma Laboratory Services midpoint growth guided to 7.9% and diagnostics up only 20 bps.
- companyQuest Diagnostics
Raised 2026 revenue growth on Oct. 22 to 9.5% at the midpoint, citing testing volume up 14.5% and partner-driven growth; disclosed unauthorized access to a test ordering system.
- partnerCorewell Health
Named as a new relationship contributing to Quest’s testing volume growth.
- partnerFresenius Medical Care
Named as a new relationship contributing to Quest’s testing volume growth.
- regulatory factorMedicare PAMA
Proposed changes to Medicare lab fees starting 2027, cited as a shared headwind for both companies.


